Table 1. EpCAM-directed immunotherapeutic approaches in clinical development.

Therapeutic (Alternative Name)	Class	Ongoing or recently completed trials	Dosing	Company
Catumaxomab (Removab®)	Trispecific antibody; mouse IgG2a/rat IgG2b hybrid	Phase II/III in ovarian cancer Phase II in gastric cancer	i.p., escalating dose from 10–200 μg	Trion Pharma/Fresenius Biotech
Proxinium® Vivendium® (VB4-845)	Immunotoxin; single-chain antibody pseudomonas exotoxin fusion	Phase II/III in head and neck cancer Phase I/II in bladder cancer	Intratumoral; up to 4 mg day−1 Intra-bladder	Viventia
IGN-101 (edrecolomab)	Vaccine for induction of anti-idiotypic antibody response	Phase II in various adenocarcinoma Phase II/III in non-small cell lung cancer	Multiple s.c.; 0.5 mg	Aphton
Adecatumumab (MT201)	Fully human IgG1 mAb	Phase II in metastatic breast and early-stage prostate cancer Phase I in metastatic breast, plus Taxotere	i.v.; 2 and 6 mg kg−1; 2-week interval i.v.; 4 and 13 mg kg−1 3-week interval	Micromet, Inc./Serono
ING-1	Human engineered IgG1 mAb	Phase I in various adenocarcinoma	i.v. or s.c.; up to 6 × 1 mg kg−1 (MTD)	Xoma, Inc.
EMD 273 066 (huKS-IL2)	Fusion of humanized mAb KS1/4 with human IL-2	Phase I in hormone-refractory prostate cancer	i.v.; up to 6.4 mg m2 day−1 (MTD)	Lexigen, Inc./Merck KGa
Various Vaccines	Extracellular domain of EpCAM; EpCAM encoding viruses	Phase I trials in various adenocarcinoma	s.c.	Academically sponsored

EpCAM=epithelial cell adhesion activating molecule; i.p=intraperitoneal; i.v=intravenous; MTD=maximum tolerated dose; s.c=subcutaneous.